Aniracetam
AMpaMet · sarpul · anixiku · draganon · Anisitan · Ro 13-3057 · RO 13-5057 · ANIRACETAM
Identifikatoren & physikalische Daten
| CAS No. | 72432-10-1 |
|---|---|
| Summenformel | C12H13NO3 |
| Durchschnittliche Molmasse | 219,24 g/mol |
| Monoisotopische Masse | 219,08954328 g/mol |
| SMILES | COc1ccc(C(=O)N2CCCC2=O)cc1 |
| InChIKey | ZXNRTKGTQJPIJK-UHFFFAOYSA-N |
| PubChem CID | 2196 |
| ChEMBL | CHEMBL36994 |
| ChEBI | CHEBI:47943 |
| EC No. | 615-758-3 |
| DTXSID | DTXSID5045128 |
Chemische & physikalische Eigenschaften
| XLogP | 1,6 |
|---|---|
| Polarare Oberfläche (TPSA) | 46,6 |
| H-Brücken-Donoren | 0 |
| H-Brücken-Akzeptoren | 3 |
| Frei drehbare Bindungen | 2 |
| Schwere Atome | 16 |
| Formalladung | 0 |
| Komplexität | 282 |
| Arzneimittel | Pharmaceuticals -> Synthetic Cannabinoids or Psychoactive CompoundsPharmaceuticals -> Listed in ZINC15 |
| LogP (Verteilungskoeffizient) | 0.93 |
| Endocrine Disruptors | Potential endocrine disrupting compound |
| Collision Cross Section | 145.49 Ų [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]146.6 Ų [M+H]+ [CCS Type: TW |
| Schmelzpunkt | 121-122C |
| Siedepunkt | 399.7±34.0 °C(Predicted) |
| Dichte | 1.236±0.06 g/cm3(Predicted) |
| Lagerbedingungen | Sealed in dry,Room Temperature |
| Löslichkeit | Chloroform (Slightly), Methanol (Slightly)Soluble in chloroform. Also soluble in ethanol. Insoluble in water |
| pKa (Säurekonstante) | -1.74±0.20(Predicted) |
| Aggregatzustand | Solid |
| Farbe | White |
| Merck | 14,662 |
| InChI | InChI=1S/C12H13NO3/c1-16-10-6-4-9(5-7-10)12(15)13-8-2-3-11(13)14/h4-7H,2-3,8H2,1H3 |
| InChIKey | ZXNRTKGTQJPIJK-UHFFFAOYSA-N |
| SMILES | N1(C(=O)C2=CC=C(OC)C=C2)CCCC1=O |
| CAS Datenbank | 72432-10-1(CAS DataBase Reference) |
Sicherheit & Vorschriften
| GHS-Einstufung | This chemical does not meet GHS hazard criteria for 33.3% (1 of 3) of reports.WarningH361 (66.7%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]P203, P280, P318, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 3 reports by companies from 2 notifications to the ECHA C&L Inventory. |
|---|---|
| Hazard Classes and Categories | Repr. 2 (66.7%) |
| Wassergefährdungsklasse (WGK) | 2 |
| Zollcode | 2933.79.1500 |
| RTECS-Nr. | UY5781900 |
| Toxizität | LD50 in rats, mice (mg/kg): ~4500, >5000 orally (Cumin) |
Anwendungen & Verwendung
Beschreibung
Aniracetam, also known as N-anisoyl-2-pyrrolidinone, together with piracetam and nefiracetam, belong to the same class of piracetam metabolized drugs of brain cells. It is a non-NMDA receptor agent useful for the treatment of cognitive impairment. These drugs can enhance the activity of synaptic neurons phospholipase, increase the ATP formation and transport in brain, increase protein synthesis and RNA, promote the usage of brain on amino acids, phospholipids, glucose and oxygen, increase the patient's response, excitability and memory. Aniracetam has a higher effect than piracetam, but with a relatively minor side effect. It is well tolerated and efficacious in improving velocity and accuracy of the saccades, complex reaction time, and other aspects of performance.
Verwenden
Aniracetam is AMPA receptor potentiator with Cognition enhancer related to Piracetam. It is used as a nootropic drug to ameliorate memory and attention disturbances accompanying cerebrovascular diseases and degenerative brain disorders. Compound with anti-depressive properties used as a mental performance enhancer. Slows the rate of ion-channel closing.
Herstellung & Synthese
synthetische
Aniracetam is prepared by condensing 2-pyrrolidone with 4-methoxybenzoyl chloride. The drug was first made in the 1970s by Hoffmann-La Roche. This piracetam-related cognition enhancer reduces glutamate receptor desensitization.